

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of December

	31.12.2020	31.12.2019
	BGN'000	BGN'000
ASSETS		
Non-current assets		
Property, plant and equipment	37 729	26 981
Intangible assets	3 254	2 725
Assets with usable assets	210	420
Trade receivables	4 949	4 930
Total non-current assets	46 142	35 056
Current assets		
Inventories	10 525	8 763
Trade and other receivables	60 006	74 020
Current corporate income tax	-	-
Treasury shares redeemed	1	1
Cash and cash equivalents	46	40
Total current assets	70 578	82 824
Total assets	116 720	117 880
LIABILITIES		
Equity		
Share capital	82 200	82 200
Reserves	11 775	11 775
Retained earnings	2 912	2 568
Total	96 887	96 543
Non-current liabilities		
Long-term loans	1 662	2 037
Deferred tax liabilities	1 308	1 308
Retirement benefit obligations	159	159
Total non-current liabilities	3 129	3 504
Current liabilities		
Trade and other liabilities	6 165	7 095
Short-term loans	9 783	9 784
Current portion of long-term loans	610	616
Current corporate income tax		142
Other tax liabilities	146	196
Total current liabilities	16 704	17 833
Total liabilities	19 833	21 337
Total equity and liabilities	116 720	117 880

Date of preparation: 25.01.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of December 2020

	31.12.2020	31.12.2019
	BGN'000	BGN'000
Revenue	39 747	34 443
Other income	283	281
Total income	40 030	34 724
Carrying amount of goods sold	(817)	(748)
Changes in inventories of finished products and work in progress	(784)	1 734
Materials and services	(28 401)	(24 078)
Personnel expenses	(4 776)	(4 359)
Depreciation / amortisation expenses	(4 231)	(3 526)
Other expenses	(658)	(803)
Finance income	575	385
Finance costs	(384)	(366)
Total expenses	(39 476)	(31 761)
Profit before taxation	554	2 963
Corporate income tax expense	(210)	(395)
Profit/Loss for the period	344	2 568 (25)
Total comprehensive income for the period	344	2 543
Earnings per share / in BGN per 1 share /	0.004	0.03

Date of preparation: 25.01.2021

Sofia

Prepared by:.....
/ P. Moneva /

Executive Director:.....
/B. Georgiev/



Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of December 2020

	31.12.2020	31.12.2019
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	35 208	30 470
Payments to suppliers of materials, goods and services	(23 135)	(17 623)
Payments to personnel	(4 404)	(4 249)
Payments of interest and dividends	(352)	(339)
Other proceeds / payments	(4 075)	(6 035)
Net cash flows	3 242	2 224
Cash flows from investing activities		
Payments on non-current assets acquired	(2 819)	(1 170)
Net cash flows	(2 819)	(1 170)
Cash flows from financial activities		
Proceeds from loans	200	217
Payments on loans	(201)	(215)
Payment of interest, dividends	(214)	(197)
Payments on finance lease	(202)	(1 073)
Other proceeds/payments from treasury shares		4
Net cash flows	(417)	(1 264)
Change in cash and cash equivalents	6	(210)
Cash and cash equivalents at the beginning of the period	40	250
Cash and cash equivalents at the end of the period	46	40

Date of preparation: 25.01.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive

Director:.....

/B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of December 2020

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2019	72 200	4 124	6 477	11 199	94 000
Profit/loss for the period				2 568	2 568
Other comprehensive income		(25)			(25)
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		(25)		2 568	2 543
Issue of shares by the owners	10 000			(10 000)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			1 199	(1 199)	
Total amount of income and expenses recognised during the period	10 000		1 199	(11 199)	
Balance as of 31.12.2019	82 200	4 099	7 676	2 568	96 543
Balance as of 01.01.2020	82 200	4 099	7 676	2 568	96 543
Profit/loss for the period				344	344
Other comprehensive income					
Total comprehensive income				344	344
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.12.2020	82 200	4 099	7 676	2 912	96 887

Date of preparation: 25.01.2021
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev /

